Clinical Cancer Research, Vol 1, Issue 12 1463-1469, Copyright © 1995 by American Association for Cancer Research

ARTICLES

p53 antibodies in patients with various types of cancer: assay, identification, and characterization

R Lubin, B Schlichtholz, JL Teillaud, E Garay, A Bussel and CP Wild
Unite 301 Institut National de la Sante et de la Recherche Medicale, Institut de Genetique Moleculaire, 27 rue J. Dodu, 75010 Paris, France.

Alteration of the p53 gene is the most frequent genetic alteration in human cancer and leads to the accumulation of mutant p53 in the nucleus of tumor cells. In addition, it has been shown that patients with various types of neoplasia have p53 antibodies in their sera which could be used as an indirect diagnostic procedure for p53 alteration. Using a new ELISA, we have analyzed the sera from more than 1000 patients with various types of cancer and from healthy blood donors. We demonstrate that p53 antibodies are detected mainly in cancer patients and are strictly proportional to the occurrence of p53 mutations. Using various immunological approaches, these antibodies were unambiguously demonstrated to be directed toward the human p53 protein. Isotyping analysis of these antibodies strongly suggested that they correspond to a humoral response to the p53 protein which accumulates in the tumor cell. This finding suggests that serological analysis, combined with histochemistry, is suitable for assessing the integrity of the p53 gene in cancer patients.

This article has been cited by other articles:

				G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini Vaccination of patients with solid tumours Ann. Onc., June 1, 2003; 14(6): 817 - 824. [Abstract] [Full Text] [PDF]

				E. Kaufman and I. B. Lamster THE DIAGNOSTIC APPLICATIONS OF SALIVA-- A REVIEW Crit. Rev. Oral. Biol. Med., March 1, 2002; 13(2): 197 - 212. [Abstract] [Full Text]

				R. Parasole, F. Izzo, F. Perrone, S. Pignata, M. G. Galati, E. Leonardi, F. Castiglione, R. Orlando, G. Castello, G. Esposito, et al. Prognostic Value of Serum Biological Markers in Patients with Hepatocellular Carcinoma Clin. Cancer Res., November 1, 2001; 7(11): 3504 - 3509. [Abstract] [Full Text] [PDF]

				M Abu-Shakra, D Buskila, M Ehrenfeld, K Conrad, and Y Shoenfeld Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies Ann Rheum Dis, May 1, 2001; 60(5): 433 - 441. [Abstract] [Full Text] [PDF]

				T. Soussi p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review Cancer Res., April 1, 2000; 60(7): 1777 - 1788. [Abstract] [Full Text]

				J. Rohayem, P. Diestelkoetter, B. Weigle, A. Oehmichen, M. Schmitz, J. Mehlhorn, K. Conrad, and E. P. Rieber Antibody Response to the Tumor-associated Inhibitor of Apoptosis Protein Survivin in Cancer Patients Cancer Res., April 1, 2000; 60(7): 1815 - 1817. [Abstract] [Full Text]

				J. Rohayem, K. Conrad, T. Zimmermann, and K.-H. Frank Comparison of the Diagnostic Accuracy of Three Commercially Available Enzyme Immunoassays for Anti-p53 Antibodies Clin. Chem., November 1, 1999; 45(11): 2014 - 2016. [Full Text] [PDF]

				E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]

				B. Royer, D. Cazals-Hatem, J. Sibilia, F. Agbalika, J.-M. Cayuela, T. Soussi, F. Maloisel, J.-P. Clauvel, J.-C. Brouet, and X. Mariette Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses Blood, July 15, 1997; 90(2): 766 - 775. [Abstract] [Full Text] [PDF]